Literature DB >> 1704297

Increased CD5-positive B lymphocytes in type I diabetes.

A Muñoz1, T Gallart, O Viñas, R Gomis.   

Abstract

CD5+ B lymphocytes have been implicated in the production of polyspecific and monospecific antibodies that bind self-antigens, and increased proportions of this B cell subset occur in patients with some autoimmune diseases. We investigated the proportion of peripheral blood CD5+ B lymphocytes in type I diabetic patients. Compared with 18 age-matched healthy subjects, 11 out of 28 (39.2%) type I diabetic patients had increased proportions of circulating CD5. B lymphocytes with no alterations in the numbers of circulating B and T lymphocytes. Although all patients with increased CD5 B lymphocytes also had serum islet cell antibodies and/or insulin autoantibodies, the occurrence of increased proportions of CD5+ B lymphocytes and serum autoantibodies was not significantly correlated. Increased proportions of CD5+ B lymphocytes was not related to the time elapsed since the clinical onset of diabetes. In addition, regardless of being increased or normal, the proportion of CD5+ B lymphocytes appeared as a relatively constant phenotype after 1 year of follow-up studies at 3-month intervals in eight patients. Although the significance of these findings remains to be established, the possibility exists that CD5+ cells play a role in the pathogenesis of type I diabetes.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1704297      PMCID: PMC1535266          DOI: 10.1111/j.1365-2249.1991.tb05632.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  33 in total

1.  Immunology and Diabetes Workshop: report on the Third International (Stage 3) Workshop on the Standardisation of Cytoplasmic Islet Cell Antibodies. Held in New York, New York, October 1987.

Authors:  C Boitard; E Bonifacio; G F Bottazzo; H Gleichmann; J Molenaar
Journal:  Diabetologia       Date:  1988-07       Impact factor: 10.122

2.  Marked increase of CD5 + B cells in hyperthyroid Graves' disease.

Authors:  Y Iwatani; N Amino; T Kaneda; K Ichihara; H Tamaki; J Tachi; F Matsuzuka; S Fukata; K Kuma; K Miyai
Journal:  Clin Exp Immunol       Date:  1989-11       Impact factor: 4.330

Review 3.  CD5+ B lymphocytes, polyreactive antibodies and the human B-cell repertoire.

Authors:  P Casali; A L Notkins
Journal:  Immunol Today       Date:  1989-11

4.  Cell surface antigen CD5 is a marker for activated human B cells.

Authors:  C Werner-Favre; T L Vischer; D Wohlwend; R H Zubler
Journal:  Eur J Immunol       Date:  1989-07       Impact factor: 5.532

Review 5.  The CD5 B cell.

Authors:  T J Kipps
Journal:  Adv Immunol       Date:  1989       Impact factor: 3.543

6.  Genetic influence on the levels of circulating CD5 B lymphocytes.

Authors:  T J Kipps; J H Vaughan
Journal:  J Immunol       Date:  1987-08-15       Impact factor: 5.422

7.  Expression and regulation of CD5 on in vitro activated human B cells.

Authors:  A S Freedman; G Freeman; J Whitman; J Segil; J Daley; H Levine; L M Nadler
Journal:  Eur J Immunol       Date:  1989-05       Impact factor: 5.532

8.  Probing the normal and autoimmune B cell repertoire with Epstein-Barr virus. Frequency of B cells producing monoreactive high affinity autoantibodies in patients with Hashimoto's disease and systemic lupus erythematosus.

Authors:  M Nakamura; S E Burastero; Y Ueki; J W Larrick; A L Notkins; P Casali
Journal:  J Immunol       Date:  1988-12-15       Impact factor: 5.422

9.  Rheumatoid factor secretion from human Leu-1+ B cells.

Authors:  R R Hardy; K Hayakawa; M Shimizu; K Yamasaki; T Kishimoto
Journal:  Science       Date:  1987-04-03       Impact factor: 47.728

10.  Human lymphocytes making rheumatoid factor and antibody to ssDNA belong to Leu-1+ B-cell subset.

Authors:  P Casali; S E Burastero; M Nakamura; G Inghirami; A L Notkins
Journal:  Science       Date:  1987-04-03       Impact factor: 47.728

View more
  7 in total

1.  Analysis of lymphocyte phenotypes in cord blood from early gestation fetuses.

Authors:  M Peakman; A G Buggins; K H Nicolaides; D M Layton; D Vergani
Journal:  Clin Exp Immunol       Date:  1992-11       Impact factor: 4.330

2.  Early T-cell defects in pre-type 1 diabetes.

Authors:  L al Sakkaf; P Pozzilli; P J Bingley; M W Lowdell; J M Thomas; E Bonifacio; E A Gale; G F Bottazzo
Journal:  Acta Diabetol       Date:  1992       Impact factor: 4.280

Review 3.  Immune aging in diabetes and its implications in wound healing.

Authors:  J Moura; P Madureira; E C Leal; A C Fonseca; E Carvalho
Journal:  Clin Immunol       Date:  2019-02-05       Impact factor: 3.969

4.  Lymphocyte subset abnormalities, autoantibodies and their relationship with HLA DR types in children with type 1 (insulin-dependent) diabetes and their first degree relatives.

Authors:  M Peakman; T Warnock; A Vats; G L McNab; J Underhill; P T Donaldson; D Vergani
Journal:  Diabetologia       Date:  1994-02       Impact factor: 10.122

5.  Anti-islet cell and anti-insulin antibody production by CD5+ and CD5- B lymphocytes in IDDM.

Authors:  A Muñoz; T Gallart; E F Usac; J Fernández-Alvarez; O Viñas; N Somoza; J Barceló; R Gomis
Journal:  Diabetologia       Date:  1995-01       Impact factor: 10.122

6.  Analysis of ancestral and functionally relevant CD5 variants in systemic lupus erythematosus patients.

Authors:  Maria Carmen Cenit; Mario Martínez-Florensa; Marta Consuegra; Lizette Bonet; Elena Carnero-Montoro; Noelia Armiger; Miguel Caballero-Baños; Maria Teresa Arias; Daniel Benitez; Norberto Ortego-Centeno; Enrique de Ramón; José Mario Sabio; Francisco J García-Hernández; Carles Tolosa; Ana Suárez; Miguel A González-Gay; Elena Bosch; Javier Martín; Francisco Lozano
Journal:  PLoS One       Date:  2014-11-17       Impact factor: 3.240

7.  Expansion of FasL-Expressing CD5+ B Cells in Type 1 Diabetes Patients.

Authors:  Ankit Saxena; Hideo Yagita; Thomas W Donner; Abdel Rahim A Hamad
Journal:  Front Immunol       Date:  2017-04-07       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.